Intrathecal rituximab therapy in multiple sclerosis: Review of evidence supporting the need for future trials

Current Drug Targets

Volumn 15, Issue 13, 2014, Pages 1205-1214

  Bonnan, Mickael ^a   Ferrari, Sylvie ^a   Bertandeau, Eric ^a   Demasles, Stéphanie ^a   Krim, Elsa ^a   Miquel, Marie ^a   Barroso, Bruno ^a  

^a Hospital F Mitterrand   (France)

Author keywords

Chronic progressive; Intrathecal injection; Lymphoma; Multiple sclerosis; Rituximab

Indexed keywords

ALEMTUZUMAB; CD16 ANTIGEN; CD20 ANTIGEN; CD3 ANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 15; INTERLEUKIN 2; METHOTREXATE; METHYLPREDNISOLONE; RITUXIMAB; SYNDECAN 1; TRASTUZUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BRAIN CORTEX LESION; CELL ACTIVATION; CELL MEDIATED CYTOTOXICITY; CELLULAR IMMUNITY; CLINICAL EFFECTIVENESS; DISEASE COURSE; DRUG DISTRIBUTION; DRUG MECHANISM; DRUG SAFETY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY DISEASE; LYMPHOMA; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NON-HODGKIN LYMPHOMA CELL LINE; NONHUMAN; OPSOCLONUS MYOCLONUS SYNDROME; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); SURVIVAL; ANIMAL; BLOOD BRAIN BARRIER; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; INTRASPINAL DRUG ADMINISTRATION; LYMPHOMA, B-CELL; PATHOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; BLOOD-BRAIN BARRIER; CLINICAL TRIALS AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, SPINAL; LYMPHOMA, B-CELL; MULTIPLE SCLEROSIS;

EID: 84922252365     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450115666141029234644     Document Type: Article

References (108)

1. Castillo-Trivino T, Braithwaite D, Bacchetti P, Waubant E. Rituximab in relapsing and progressive forms of multiple sclerosis: a systematic review. PLoS One 2013; 8(7): e66308.
2. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66(4): 460-71.
3. Bowen JD, Kraft GH, Wundes A, et al. Autologous hematopoietic cell transplantation following high-dose immunosuppressive therapy for advanced multiple sclerosis: long-term results. Bone Marrow Transplant 2012; 47(7): 946-51.
4. Mondria T, Lamers CHJ, te Boekhorst PAW, Gratama JW, Hintzen RQ. Bone-marrow transplantation fails to halt intrathecal lymphocyte activation in multiple sclerosis. J Neurol, Neurosurg Psychiat 2008; 79(9): 1013-5.
5. von Budingen HC, Bar-Or A, Zamvil SS. B cells in multiple sclerosis: connecting the dots. Curr Opin Immunol 2011; 23(6): 713-20.
6. Bonnan M. Intrathecal immune reset in multiple sclerosis: exploring a new concept. Med Hypotheses 2014; 82: 300-9.
7. Weiner GJ. Rituximab: mechanism of action. Semin Hematol 2010; 47(2): 115-23.
8. Kuijpers TW, Bende RJ, Baars PA, et al. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J Clin Invest 2010; 120(1): 214-22.
9. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med 2014; 11: 20-33.
10. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003; 48(2): 455-9.
11. Harjunpaa A, Wiklund T, Collan J, et al. Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma. Leuk Lymphoma 2001; 42(4): 731-8.
12. Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood 2003; 101(2): 466-8.
13. Martin MdP, Cravens PD, Winger R, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66(8): 1016-20.
14. Ruhstaller TW, Amsler U, Cerny T. Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol 2000; 11(3): 374-5.
15. Rubenstein JL, Fridlyand J, Abrey L, et al. Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. J Clin Oncol 2007; 25(11): 1350-6.
16. Crocchiolo R, Ciccolini J, El-Cheikh J, Furst S, Castagna L, Granata A, et al. Successful treatment of post-transplant Epstein-Barr virus-related meningoencephalitis by intravenous rituximab monotherapy. Leuk Lymphoma 2012; 53(10): 2063-5.
17. Rubenstein JL, Li J, Chen L, et al. Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma. Blood 2013; 121(5): 745-51.
18. Philippe G, Isabelle J, Gilles P, et al. Very low residual concentrations of rituximab long after infusion still induce positive B-cell complement-dependent cytotoxicity-crossmatch. Hum Immunol 2013; 74(12): 1616-8.
19. Kadoch C, Li J, Wong VS, et al. Complement activation and intraventricular rituximab distribution in recurrent central nervous system lymphoma. Clin Cancer Res 2014; 20(4): 1029-41.
20. Pulido JS, Bakri SJ, Valyi-Nagy T, Shukla D. Rituximab penetrates full-thickness retina in contrast to tissue plasminogen activator control. Retina 2007; 27(8): 1071-3.
21. Itty S, Olson JH, O'Connell DJ, Pulido JS. Treatment of primary intraocular lymphoma (PIOL) has involved systemic, intravitreal or intrathecal chemotherapy and/or radiotherapy. Retina 2009; 29(3): 415-6.
22. Shahar J, Avery RL, Heilweil G, et al. Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 2006; 26(3): 262-9.
23. Trbojevic-Cepe M, Brinar V, Pauro M, Vogrinc Z, Stambuk N. Cerebrospinal fluid complement activation in neurological diseases. J Neurol Sci 1998; 154(2): 173-81.
24. Dujardin BC, Driedijk PC, Roijers AF, Out TA. The determination of the complement components C1q, C4 and C3 in serum and cerebrospinal fluid by radioimmunoassay. J Immunol Methods 1985; 80(2): 227-37.
25. Mook-Kanamori BB, Brouwer MC, Geldhoff M, Ende AV, van de Beek D. Cerebrospinal fluid complement activation in patients with pneumococcal and meningococcal meningitis. J Infect 2014; 68(6): 542-7
26. Kossmann T, Stahel PF, Morganti-Kossmann MC, Jones JL, Barnum SR. Elevated levels of the complement components C3 and factor B in ventricular cerebrospinal fluid of patients with traumatic brain injury. J Neuroimmunol 1997; 73(1-2): 63-9.
27. Barun B, Bar-Or A. Treatment of multiple sclerosis with anti-CD20 antibodies. Clin Immunol 2012; 142(1): 31-7.
28. Pranzatelli MR, Slev PR, Tate ED, Travelstead AL, Colliver JA, Joseph SA. Cerebrospinal fluid oligoclonal bands in childhood opsoclonus-myoclonus. Pediatr Neurol 2011; 45(1): 27-33.
29. Pranzatelli MR, Tate ED, Travelstead AL, Colliver JA. Long-term cerebrospinal fluid and blood lymphocyte dynamics after rituximab for pediatric opsoclonus-myoclonus. J Clin Immunol 2010; 30(1): 106-13.
30. Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonusmyoclonus syndrome. Pediatrics 2005; 115(1): e115-9.
31. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28(9): 585-93.
32. Pranzatelli MR, Tate ED, Shenoy S, Travelstead AL. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus. Pediatr Blood Cancer 2012; 58(6): 988-91.
33. Baumhefner RW, Booe MM, Tourtellotte WW. Modulation of de novo CNS IgG synthesis with preservation of oligoclonal IgG in multiple sclerosis. Neurology 1979; 29: 549.
34. Tourtellotte WW, Ma BI. Multiple sclerosis: the blood-brainbarrier and the measurement of de novo central nervous system IgG synthesis. Neurology 1978; 28(9 Pt 2): 76-83.
35. Stüve O, Cepok S, Elias B, et al. Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis. Arch Neurol 2005; 62(10): 1620-3.
36. Petereit HF, Moeller-Hartmann W, Reske D, Rubbert A. Rituximab in a patient with multiple sclerosis--effect on B cells, plasma cells and intrathecal IgG synthesis. Acta Neurol Scand 2008; 117(6): 399-403.
37. Cross AH, Stark JL, Lauber J, Ramsbottom MJ, Lyons J-A. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol 2006; 180(1-2): 63-70.
38. Piccio L, Naismith RT, Trinkaus K, et al. Changes in B-and Tlymphocyte and chemokine levels with rituximab treatment in multiple sclerosis. Arch Neurol 2010; 67(6): 707-14.
39. Bielekova B, Herman ML. Method of treating multiple sclerosis by intrathecal depletion of B cells and biomarkers to select patients with progressive multiple sclerosis. Patent Pub No WO/2013/049362, 2013.
40. Monson NL, Cravens PD, Frohman EM, Hawker K, Racke MK. Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. Arch Neurol 2005; 62(2): 258-64.
41. Dietlein M, Pels H, Schulz H, et al. Imaging of central nervous system lymphomas with iodine-123 labeled rituximab. Eur J Haematol 2005; 74(4): 348-52.
42. Beauchesne P. Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol 2010 Sep; 11(9): 871-9.
43. Schlegel U, Pels H, Glasmacher A, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study. J Neurol Neurosurg Psychiatry 2001; 71(1): 118-22.
44. Tai WM, Chung J, Tang PL, et al. Central nervous system (CNS) relapse in diffuse large B cell lymphoma (DLBCL): pre-and postrituximab. Ann Hematol 2011; 90(7): 809-18.
45. Schulz H, Pels H, Schmidt-Wolf I, Zeelen U, Germing U, Engert A. Intraventricular treatment of relapsed central nervous system lymphoma with the anti-CD20 antibody rituximab. Haematologica 2004; 89(6): 753-4.
46. Bromberg JE, Doorduijn JK, Baars JW, van Imhoff GW, Enting R, van den Bent MJ. Acute painful lumbosacral paresthesia after intrathecal rituximab. J Neurol 2012; 259(3): 559-61.
47. Maximiano Alonso C, Sanchez Ruiz AC, Cantos Sanchez deIbarguen B, Mendez Garcia M, Ronco IS, Provencio Pulla M. Ocular relapse of primary brain lymphoma in immunocompetent patient, treated with intrathecal rituximab. Clin Transl Oncol 2010; 12(10): 701-3.
48. Antonini G, Cox MC, Montefusco E, et al. Intrathecal anti-CD20 antibody: an effective and safe treatment for leptomeningeal lymphoma. J Neurooncol 2007; 81(2): 197-9.
49. Twombley K, Pokala H, Ardura MI, et al. Intraventricular rituximab and systemic chemotherapy for treatment of central nervous system post-transplant lymphoproliferative disorder after kidney transplantation. Pediatr Transplant 2012; 16(6): E201-9.
50. Bonney DK, Htwe EE, Turner A, et al. Sustained response to intrathecal rituximab in EBV associated Post-transplant lymphoproliferative disease confined to the central nervous system following haematopoietic stem cell transplant. Pediatr Blood Cancer 2012; 58(3): 459-61.
51. van de Glind G, de Graaf S, Klein C, Cornelissen M, Maecker B, Loeffen J. Intrathecal rituximab treatment for pediatric posttransplant lymphoproliferative disorder of the central nervous system. Pediatr Blood Cancer 2008; 50(4): 886-8.
52. Chamberlain MC, Johnston SK, Van Horn A, Glantz MJ. Recurrent lymphomatous meningitis treated with intra-CSF rituximab and liposomal ara-C. J Neurooncol 2009; 91(3): 271-7.
53. Czyzewski K, Styczynski J, Krenska A, et al. Intrathecal therapy with rituximab in central nervous system involvement of posttransplant lymphoproliferative disorder. Leuk Lymphoma 2013; 54(3): 503-6.
54. Liu CY, Teng HW, Lirng JF, Chiou TJ, Chen PM, Hsiao LT. Sustained remission and long-term survival of secondary central nervous system involvement by aggressive B-cell lymphoma after combination treatment of systemic high-dose chemotherapy and intrathecal rituximab. Leuk Lymphoma 2008; 49(10): 2018-21.
55. Itty S, Pulido JS. Rituximab for intraocular lymphoma. Retina (Philadelphia, Pa). 2009; 29(2): 129-32.
56. Pels H, Schulz H, Manzke O, Hom E, Thall A, Engert A. Intraventricular and intravenous treatment of a patient with refractory primary CNS lymphoma using rituximab. J Neurooncol 2002; 59(3): 213-6.
57. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94(7): 2217-24.
58. Wong ET, Tishler R, Barron L, Wu JK. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphomas. Cancer 2004; 101(1): 139-45.
59. Reynolds R, Roncaroli F, Nicholas R, Radotra B, Gveric D, Howell O. The neuropathological basis of clinical progression in multiple sclerosis. Acta Neuropathol 2011; 122(2): 155-70.
60. Popescu BF, Lucchinetti CF. Meningeal and cortical grey matter pathology in multiple sclerosis. BMC neurology 2012; 12: 11.
61. Antulov R, Carone DA, Bruce J, et al. Regionally distinct white matter lesions do not contribute to regional gray matter atrophy in patients with multiple sclerosis. J Neuroimaging 2011; 21(3): 210-8.
62. Bø L, Geurts JJ, van der Valk P, Polman C, Barkhof F. Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 2007 Jan; 64(1): 76-80.
63. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128(Pt 11): 2705-12.
64. Kutzelnigg A, Faber-Rod JC, Bauer J, et al. Widespread demyelination in the cerebellar cortex in multiple sclerosis. Brain Pathol 2007; 17(1): 38-44.
65. Geurts JJ, Bo L, Roosendaal SD, et al. Extensive hippocampal demyelination in multiple sclerosis. J Neuropathol Exp Neurol 2007; 66(9): 819-27.
66. Calabrese M, Poretto V, Favaretto A, et al. Cortical lesion load associates with progression of disability in multiple sclerosis. Brain 2012; 135(Pt 10): 2952-61.
67. Magliozzi R, Howell O, Vora A, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130(Pt 4): 1089-104.
68. Howell OW, Reeves CA, Nicholas R, et al. Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis. Brain 2011; 134(Pt 9): 2755-71.
69. Magliozzi R, Howell OW, Reeves C, et al. A Gradient of neuronal loss and meningeal inflammation in multiple sclerosis. Ann Neurol 2010; 68(4): 477-93.
70. Choi SR, Howell OW, Carassiti D, et al. Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis. Brain 2012; 135(Pt 10): 2925-37.
71. Bonnan M. Does disease-irrelevant intrathecal synthesis in multiple sclerosis make sense in the light of tertiary lymphoid organs? Front Neurol 2014; 5: 27.
72. Haugen M, Frederiksen JL, Degn M. B cell follicle-like structures in multiple sclerosis-With focus on the role of B cell activating factor. J Neuroimmunology 2014; 273: 1-7.
73. Bonnan M. Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments. Mult Scler Int 2014; submitted.
74. Lu J SJ. Continued disease activity in a patient with multiple sclerosis after allogeneic hematopoietic cell transplantation. Arch Neurol 2009; 66(1): 116-20.
75. Fox RJ, Thompson A, Baker D, et al. Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS. Mult Scler 2012; 18(11): 1534-40.
76. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012; 380(9856): 1829-39.
77. Inglese M, Mancardi GL, Pagani E, et al. Brain tissue loss occurs after suppression of enhancement in patients with multiple sclerosis treated with autologous haematopoietic stem cell transplantation. J Neurol Neurosurg Psychiatry 2004; 75(4): 643-4.
78. Nash RA, Bowen JD, McSweeney PA, et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe Multiple sclerosis. Blood 2003; 102(7): 2364-72.
79. Rocca MA, Mondria T, Valsasina P, et al. A three-year study of brain atrophy after autologous hematopoietic stem cell transplantation in rapidly evolving secondary progressive. Mult Scler AJNR Am J Neuroradiol 2007; 28(9): 1659-61.
80. Meinl E, Krumbholz M, Derfuss T, Junker A, Hohlfeld R. Compartmentalization of inflammation in the CNS: a major mechanism driving progressive. Mult Scler J Neurol Sci 2008; 274(1-2): 42-4.
81. Frischer JM, Bramow S, Dal-Bianco A, et al. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132(Pt 5): 1175-89.
82. Russi AE, Brown MA. The meninges: new therapeutic targets for multiple sclerosis. Transl Res 2014; pii: S1931-5244(14)00304-1
83. Cepok S, Rosche B, Grummel V, et al. Short-lived plasma blasts are the main B cell effector subset during the course of multiple sclerosis. Brain 2005; 128(Pt 7): 1667-76.
84. Wilson HL. B cells contribute to MS pathogenesis through antibody-dependent and antibody-independent mechanisms. Biologics 2012; 6: 117-23.
85. Rossi S, Motta C, Studer V, et al. Tumor necrosis factor is elevated in progressive multiple sclerosis and causes excitotoxic neurodegeneration. Mult Scler 2014; 20(3): 304-12.
86. Studer V, Rossi S, Motta C, Buttari F, Centonze D. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. J Neuroimmunol 2014; pii: S0165-5728(14)00850-9.
87. Elliott C, Lindner M, Arthur A, et al. Functional identification of pathogenic autoantibody responses in patients with multiple sclerosis. Brain 2012; 135(Pt 6): 1819-33.
88. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. Ann Rheum Dis 2008; 67(3): 402-8.
89. Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells and their survival niches in autoimmunity, malignancy, and allergy. J Immunol 2012; 189(11): 5105-11.
90. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010; 236: 125-38.
91. Rosengren S, Wei N, Kalunian KC, Zvaifler NJ, Kavanaugh A, Boyle DL. Elevated autoantibody content in rheumatoid arthritis synovia with lymphoid aggregates and the effect of rituximab. Arthritis Res Ther 2008; 10(5): R105.
92. Chu VT, Berek C. The establishment of the plasma cell survival niche in the bone marrow. Immunol Rev 2013; 251(1): 177-88.
93. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of longlived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol 2008; 180(1): 361-71.
94. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-celltargeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350(25): 2572-81.
95. Thaunat O, Patey N, Gautreau C, et al. B cell survival in intragraft tertiary lymphoid organs after rituximab therapy. Transplantation 2008; 85(11): 1648-53.
96. Kamburova EG, Koenen HJ, Borgman KJ, ten Berge IJ, Joosten I, Hilbrands LB. A single dose of rituximab does not deplete B cells in secondary lymphoid organs but alters phenotype and function. Am J Transplant 2013; 13(6): 1503-11.
97. Siderov J. Care with intrathecal trastuzumab. Lancet Oncol 2006; 7(11): 888.
98. Martin M, Cravens PD, Winger R, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65(12): 1596-603.
99. Wingerchuk DM, Carter JL. Multiple sclerosis: current and emerging disease-modifying therapies and treatment strategies. Mayo Clin Proc 2014; 89(2): 225-40.
100. [100] de Andres C, Teijeiro R, Alonso B, et al. Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis. PLoS One 2012; 7(4): e34103.
101. [101] Aloisi F, Serafini B, Magliozzi R, Howell OW, Reynolds R. Detection of Epstein-Barr virus and B-cell follicles in the multiple sclerosis brain: what you find depends on how and where you look. Brain 2010; 133(Pt 12): e157.
102. [102] Chellapandian D, Das R, Zelley K, et al. Treatment of Epstein Barr virus-induced haemophagocytic lymphohistiocytosis with rituximab-containing chemo-immunotherapeutic regimens. Br J Haematol 2013; 162(3): 376-82.
103. [103] Serafini B, Rosicarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in the multiple sclerosis brain. J Exp Med 2007; 204(12): 2899-912.
104. [104] Croia C, Astorri E, Murray-Brown W, et al. Implication of Epstein-Barr virus infection in disease-specific autoreactive B cell activation in ectopic lymphoid structures of Sjogren's syndrome. Arthritis Rheumatol 2014; 66(9): 2545-57.
105. [105] Moreau T, Coles A, Wing M, Isaacs J, Hale G, Waldmann H, et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996; 119 (Pt 1): 225-37.
106. [106] Tourtellotte WW, Baumhefner RW, Potvin AR, et al. Multiple sclerosis de novo CNS IgG synthesis: effect of ACTH and corticosteroids. Neurology 1980; 30(11): 1155-62.
107. [107] Bittner S, Simon OJ, Gobel K, Bien CG, Meuth SG, Wiendl H. Rasmussen encephalitis treated with natalizumab. Neurology 2013; 81(4): 395-7.
108. [108] Stich O, Jarius S, Kleer B, Rasiah C, Voltz R, Rauer S. Specific antibody index in cerebrospinal fluid from patients with central and peripheral paraneoplastic neurological syndromes. J Neuroimmunol 2007; 183(1-2): 220-4.